Abstract
The management of patients with stages III and IV indolent non-Hodgkin’s lymphomas remains controversial. As initially reported by Jones et al [1] in 1973, the median survival for patients with ‘favorable’ histology lymphomas (Table 1) was more than 8 years, in contrast to a median survival of less than one year for those with ‘unfavorable’ histologic subtypes.1 With the use of intensive combination chemotherapy over the intervening decade, there has been dramatic improvement in the prognosis of patients with aggressive lymphomas [4], whereas there has been a virtual standstill in the development of more effective therapy for those with indolent histologies. Although complete remissions can be achieved in the majority of patients with advanced stage lymphomas of either indolent or aggressive histologic subtypes, it is only those with aggressive subtypes who experience prolonged remission durations. And with observations extending well beyond 10 years, confidence is high that such patients may be cured. The impact of this paradox is illustrated in Figs. 1 and 2 [5]. In spite of intensive therapy, patients with advanced indolent histologies experience a pattern of continuous late relapse following induction of complete remission; whereas the disease-free survival curve of complete responders with aggressive histologies reveals few relapses, all occurring within the first two years, and none subsequently. Although median disease-free survival is only 1–2 years for patients with indolent lymphomas, patients continue to live for long periods with active disease.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jones SE, Fuks Z, Bull M, et al.: Non-Hodgkin’s lymphomas: IV. Clinicopathologic correla-tion in 405 cases. Cancer 31: 806–823, 1973.
Rappaport H, Winter WJ, Hicks EB: Follicular lymphoma - A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9: 792–821, 1956.
The non-Hodgkin’s lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Cancer 49: 2112–2135, 1982.
Sweet D, Golomb H: The treatment of histiocytic lymphoma. Semin Oncol 7: 302–309, 1980.
Portlock CS: Non-Hodgkin’s lymphomas. In: Prognosis, Fries JF, Ehrlich GF (eds), The Charles Press Publishers, 1981, pp. 91–94.
Chabner BA, Johnson RE, Young RC, et al.: Sequential nonsurgical and surgical staging of non-Hodgkin’s lymphomas. Ann Intern Med 85: 149–154, 1976.
Goffinet DR, Warnke R, Dunnick NR, et al.: Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin’s lymphomas. Cancer Treat Rep 61: 981–992, 1977.
Ribas-Mundo M, Rosenberg SA: The value of sequential bone marrow biopsy and laparo-tomy and splenectomy in a series of 200 consecutive untreated patients with non-Hodgkin’s lymphoma. Eur J Cancer 15: 941–952, 1979.
Rosenberg SA: Is intensive treatment of favorable non-Hodgkin’s lymphoma necessary? In: Controversies in Oncology, Wiernik PH (ed), New York: John Wiley & Sons, 1982, pp. 45–60.
Monfardini S, Banfi A, Bonadonna G, et al.: Improved five year survival after combined radiotherapy-chemotherapy for stage I—II non-Hodgkin’s lymphoma. Int J Rad Oncol Biol Phys 6: 125–134, 1980.
Jones SE, Fuks Z, Kaplan HS, et al.: Non-Hodgkin’s lymphomas: V. Results of radiotherapy. Cancer 32: 682–291, 1973.
Chen MG, Prosnitz LR, Gonzalez-Serva A, et al.: Results of radiotherapy in control of stage I and II non-Hodgkin’s lymphoma. Cancer 43: 1245–1254, 1979.
Glatstein E, Fuks Z, Goffinet DR, et al.: Non-Hodgkin’s lymphomas of stage III extent: Is total lymphoid irradiation appropriate treatment? Cancer 37: 2806–2812, 1976.
Cox JD, Komaki R, Kun LE, Wilson JF, Greenberg M: Stage III nodular lymphoreticular tumors (non-Hodgkin’s lymphoma): Results of central lymphatic irradiation. Cancer 47: 2247–2252, 1981.
Carabell SC, Chaffey JT, Rosenthal DS, et al.: Results of total body irradiation in the treatment of advanced non-Hodgkin’s lymphomas. Cancer 43: 994–1000, 1979.
Choi NC, Timothy AR, Kaufman SD, et al.: Low dose fractionated whole body irradiation in the treatment of advanced non-Hodgkin’s lymphoma. Cancer 43: 1636–1642, 1979.
Hoppe RT, Kushlan P, Kaplan HS, et al.: The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58: 592–598, 1981.
Thar TL, Million RR, Noyes WD: Total body irradiation in non-Hodgkin’s lymphoma. Int J Radiot Biol 5: 171–176, 1979.
Young RC, Johnson RE, Canellos GP, et al.: Advanced lymphocytic lymphoma: Randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep 61: 1153–1159, 1977.
Kennedy BJ, Bloomfield CD, Kiang DT, et al.: Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 41: 23–28, 1978.
Lister TA, Cullen MH, Beard MEJ, et al.: Comparison of combined and single-agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Br Med J 1: 533–537, 1978.
Portlock CS, Rosenberg SA, Glatstein E, et al.: Treatment of advanced non-Hodgkin’s lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47: 747–756, 1976.
Anderson T, Bender RA, Fisher RI, et al.: Combination chemotherapy in non-Hodgkin’s lymphoma: Results of long-term follow-up. Cancer Treat Rep 61: 1057–1066, 1977.
Bitran JC, Golomb HM, Ultmann JE, et al.: Non-Hodgkin’s lymphoma, poorly differentiated lymphocytic and mixed cell types: Results of sequential staging procedures, response to therapy, and survival of 100 patients. Cancer 42: 88–95, 1978.
Glick JH, Barnes JM, Ezdinli EZ, et al.: Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58: 920–925, 1981.
Jones SE, Grozea PN, Metz EN, et al.: Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: A Southwest Oncology Group study. Cancer 43: 417–425, 1979.
Portlock CS, Rosenberg SA: Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin’s lymphomas. Cancer 37: 1275–1282, 1976.
Rodriquez V, Cabanillas F, Burgess MA, et al.: Combination chemotherapy (‘CHOP-Bleo’) in advanced (non-Hodgkin) malignant lymphoma. Blood 49: 325–333, 1977.
Skarin AT, Rosenthal DS, Maloney WC, et al.: Combination chemotherapy of advanced non- Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 49: 759–568, 1977.
Longo D, Hubbard S, Wesley M, et al.: Prolonged initial remission in patients with nodular mixed lymphoma (NML). Proc Am Soc Clin Oncol 22:521,1981 (abstr).
Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 58: 712–718, 1981.
Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517–522, 1982.
Peterson BA, Sartiano GP, Frizzera G, Pajak TF, Bloomfield CD, Gottlieb AJ: Symptoms in patients with favorable subtypes of non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 1: 158, 1982.
Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin’s lympho-mas of favorable histologic types. Ann Intern Med 90: 10–13, 1979.
Portlock CS: ‘Good risk’ non-Hodgkin’s lymphomas: Approaches to management. Semin Hem (in press), 1983.
Gattiker HH, Wiltshaw E, Galton DAG: Spontaneous regression in non-Hodgkin’s lymphoma. Cancer 45: 2627–2632, 1980.
Cullen MH, Lister TA, Brearley RL, et al.: Histological transformation of non-Hodgkin’s lymphoma. A prospective study. Cancer 44: 645–651, 1979.
Hubbard SM, Chabner BA, DeVita VT Jr, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC: Histologic progression in non-Hodgkin’s lymphoma. Blood 59: 258–264, 1982.
Risdall R, Hoppe RT, Warnke R: Non-Hodgkin’s lymphoma. A study of the evolution of the disease based upon 92 autopsied cases. Cancer 44: 529–542, 1979.
Kim H, Hendrickson MR, Dorfman RF: Composite lymphoma. Cancer 40: 959–976, 1977.
Cadman EC, Drislane F, Waldron J, Farber L, Prosnitz L, Bertino JR: High dose pulse chlorambucil is effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma. Cancer, 50: 1037–1041, 1982.
Zarrabi MH: Association of non-Hodgkin’s lymphoma (NHL) and second neoplasms. Semin Oncol 7: 248–259, 1980.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, Boston.
About this chapter
Cite this chapter
Portlock, C.S. (1983). The role of treatment deferral in the management of patients with advanced, indolent non-Hodgkin’s lymphomas. In: Bennett, J.M. (eds) Controversies in the Management of Lymphomas. Cancer Treatment and Research, vol 16. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3885-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3885-7_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3887-1
Online ISBN: 978-1-4613-3885-7
eBook Packages: Springer Book Archive